The global bleeding disorder testing market size was estimated to be USD 83.26 billion in 2023 and is expected to reach at USD 209.3 billion by 2033 with a CAGR of 8.74% during the forecast period 2023-2033. Increasing prevalence of hemophilic disease, rising focus on bleeding disorders such as Hemophilia A, Hemophilia B, & Von Willebrand Disease, surge in number of clinical trials, growing research & development activities, increasing awareness regarding bleeding disorders, rising development of testing instruments, growing technological advancements, surge in investment by major market players, increase in number of clinical studies using nano diagnostics for the detection of bleeding disorder, and rising launch of innovative testing products by key market players are some of the key factors boosting the market growth.
Rising launch of innovative testing products by key market players is predicted to boost the market growth during the forecast period. For instance, in July 2022, HORIBA, Ltd unveiled upgraded products within its Yumizen H500 and H550 hematology product range, offering improved performance, additional features, and greater advantages.
By Treatment, Factor replacement therapy was the highest revenue-grossing segment in the global bleeding disorder testing market in 2022 owing to the growing demand for factor replacement therapy, increasing prevalence of clotting factor deficient diseases, surge in the number of research & clinical trials for the development of factor replacement therapy medicines, and rising launch of new therapies. For instance, in November 2022, Novo Nordisk A/S has recently made ESPEROCT accessible in the United States to address hemophilia A in both adults and children. ESPEROCT is a recombinant factor VIII replacement therapy with an extended half-life, designed to prevent or decrease bleeding episodes, manage bleeding during surgery, and control bleeding in individuals with hemophilia A. Additionally, Drug therapy is predicted to grow at fastest CAGR during the forecast period owing to the increasing prevalence of bleeding disorders, growing adoption of drugs for the treatment,
By Disease, Hemophilia A was the highest revenue-grossing segment in the global bleeding disorder testing market in 2022 owing to growing prevalence of hemophilia A, increasing adoption of drugs for the treatment of hemophilia A, rising research & development activities regarding hemophilia A, surge in technological advancements, and growing launch of hematology & hemostasis analyzers. Additionally, Hemophilia B is predicted to grow at fastest CAGR during the forecast period owing to the rising prevalence of hemophilia B, growing awareness of diagnostic options, increasing research & development activities, and surge in introduction of new products. For instance, in August 2021, Siemens Healthcare GmbH has launched Sysmex's CN-3000 and CN-6000 Hemostasis Systems for conducting mid and high-volume coagulation testing, as per their agreement with Sysmex Corporation.
By End-user, Hospitals was the highest revenue-grossing segment in the global bleeding disorder testing market in 2022 owing to the increasing prevalence of bleeding disorders, growing hospitalization rate, rising demand for testing instruments & reagents in hospitals & clinics, and surge in healthcare infrastructure. Additionally, Diagnostic centres is predicted to grow at fastest CAGR during the forecast period owing to the surge in prevalence of hemophilic disease, growing awareness regarding bleeding disorders among population, rising technological advancements, and increasing launch of portable analysers. For instance, in March 2021, F. Hoffmann-La Roche has introduced Cobas pure integrated solutions in CE mark-accepting countries, aiming to streamline diagnostic procedures in small to medium-sized laboratories through the use of automation technology.
North America region is anticipated for the highest revenue share during the forecast period owing to the growing prevalence of bleeding disorders, presence of major market players, rising research & development activities, surge in approval of regulatory bodies, and increasing launch of advanced products. For instance, in May 2022, Precision Biologic Inc, a prominent hemostasis diagnostic products developer, is excited to unveil its latest CRYOcheck Chromogenic Factor IX assay in Canada, the European Union, Australia, and New Zealand. This launch comes after receiving market authorization from Health Canada and respective regulatory authorities in the mentioned countries. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the surge in number of bleeding disorders such as hemophilia A & B, increasing focus on development of testing instruments, rising technological advancements, growing investment by key market players, and surge in product approvals by regulatory bodies. For instance, in February 2023, The U.S. Food and Drug Administration (FDA) has given its approval for ALTUVIIIO [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl], formerly known as efanesoctocog alfa. It is a groundbreaking factor VIII replacement therapy, offering sustained high levels of the factor. ALTUVIIIO is intended for routine prophylaxis, on-demand treatment for controlling bleeding episodes, and perioperative management (surgery) in both adults and children diagnosed with hemophilia A.
Rising launch of innovative testing products by key market players is predicted to boost the market growth during the forecast period. For instance, in July 2022, HORIBA, Ltd unveiled upgraded products within its Yumizen H500 and H550 hematology product range, offering improved performance, additional features, and greater advantages.
By Treatment, Factor replacement therapy was the highest revenue-grossing segment in the global bleeding disorder testing market in 2022 owing to the growing demand for factor replacement therapy, increasing prevalence of clotting factor deficient diseases, surge in the number of research & clinical trials for the development of factor replacement therapy medicines, and rising launch of new therapies. For instance, in November 2022, Novo Nordisk A/S has recently made ESPEROCT accessible in the United States to address hemophilia A in both adults and children. ESPEROCT is a recombinant factor VIII replacement therapy with an extended half-life, designed to prevent or decrease bleeding episodes, manage bleeding during surgery, and control bleeding in individuals with hemophilia A. Additionally, Drug therapy is predicted to grow at fastest CAGR during the forecast period owing to the increasing prevalence of bleeding disorders, growing adoption of drugs for the treatment,
By Disease, Hemophilia A was the highest revenue-grossing segment in the global bleeding disorder testing market in 2022 owing to growing prevalence of hemophilia A, increasing adoption of drugs for the treatment of hemophilia A, rising research & development activities regarding hemophilia A, surge in technological advancements, and growing launch of hematology & hemostasis analyzers. Additionally, Hemophilia B is predicted to grow at fastest CAGR during the forecast period owing to the rising prevalence of hemophilia B, growing awareness of diagnostic options, increasing research & development activities, and surge in introduction of new products. For instance, in August 2021, Siemens Healthcare GmbH has launched Sysmex's CN-3000 and CN-6000 Hemostasis Systems for conducting mid and high-volume coagulation testing, as per their agreement with Sysmex Corporation.
By End-user, Hospitals was the highest revenue-grossing segment in the global bleeding disorder testing market in 2022 owing to the increasing prevalence of bleeding disorders, growing hospitalization rate, rising demand for testing instruments & reagents in hospitals & clinics, and surge in healthcare infrastructure. Additionally, Diagnostic centres is predicted to grow at fastest CAGR during the forecast period owing to the surge in prevalence of hemophilic disease, growing awareness regarding bleeding disorders among population, rising technological advancements, and increasing launch of portable analysers. For instance, in March 2021, F. Hoffmann-La Roche has introduced Cobas pure integrated solutions in CE mark-accepting countries, aiming to streamline diagnostic procedures in small to medium-sized laboratories through the use of automation technology.
North America region is anticipated for the highest revenue share during the forecast period owing to the growing prevalence of bleeding disorders, presence of major market players, rising research & development activities, surge in approval of regulatory bodies, and increasing launch of advanced products. For instance, in May 2022, Precision Biologic Inc, a prominent hemostasis diagnostic products developer, is excited to unveil its latest CRYOcheck Chromogenic Factor IX assay in Canada, the European Union, Australia, and New Zealand. This launch comes after receiving market authorization from Health Canada and respective regulatory authorities in the mentioned countries. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the surge in number of bleeding disorders such as hemophilia A & B, increasing focus on development of testing instruments, rising technological advancements, growing investment by key market players, and surge in product approvals by regulatory bodies. For instance, in February 2023, The U.S. Food and Drug Administration (FDA) has given its approval for ALTUVIIIO [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl], formerly known as efanesoctocog alfa. It is a groundbreaking factor VIII replacement therapy, offering sustained high levels of the factor. ALTUVIIIO is intended for routine prophylaxis, on-demand treatment for controlling bleeding episodes, and perioperative management (surgery) in both adults and children diagnosed with hemophilia A.
Segmentation: Bleeding Disorder Testing Market Report 2022 - 2033
Bleeding Disorder Testing Market Analysis & Forecast by Treatment 2022 - 2033 (Revenue USD Bn)
- Drug Therapy
- Factor Replacement Therapy
Bleeding Disorder Testing Market Analysis & Forecast by Disease 2022 - 2033 (Revenue USD Bn)
- Von Willebrand Disease
- Hemophilia A
- Hemophilia B
- Others
Bleeding Disorder Testing Market Analysis & Forecast by End-user 2022 - 2033 (Revenue USD Bn)
- Diagnostic Centres
- Hospitals
- Others
Bleeding Disorder Testing Market Analysis & Forecast by Region 2022 - 2033 (Revenue USD Bn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Bleeding Disorder Testing Market: Treatment Estimates & Trend Analysis
8. Bleeding Disorder Testing Market: Disease Estimates & Trend Analysis
9. Bleeding Disorder Testing Market: End-user Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Bleeding Disorder Testing Market
12. Europe Global Bleeding Disorder Testing Market
13. Asia Pacific Global Bleeding Disorder Testing Market
14. Latin America Global Bleeding Disorder Testing Market
15. MEA Global Bleeding Disorder Testing Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Sanofi
- Medexus Pharma Inc.
- Takeda Pharmaceutical Company Limited
- Novo Nordisk A/S
- Bayer AG
- F. Hoffmann-La Roche Ltd.
- CSL Limited
- Grifols
- S.A.
- Octapharma AG
- Pfizer Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | August 2023 |
| Forecast Period | 2022 - 2033 |
| Estimated Market Value ( USD | $ 83.26 Billion |
| Forecasted Market Value ( USD | $ 209.3 Billion |
| Compound Annual Growth Rate | 8.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
